additional file 2 - Springer Static Content Server
Recommend Documents
27. 0.23. 0.01. 0.42. B. Clone name log2 ER mean log2 ER. Growth factor activity (3). Melanoma derived growth regulatory protein. 0.62. 0.46. Midkine precursor.
The Cancer Genome Atlas (TCGA) [9] were downloaded from Broad GDAC Firehose ... miRNAs were available in the TCGA, DBCG and Micma cohorts, and 68 ...
program. (https://pypi.python.org/pypi/cutadapt) [3] is well suited for this task because it provides a ... profiling of off-âtarget cleavage by CRISPR-âCas nucleases.
Model (no. parameters). LRT test. 2âl df p value l Ï (dN/dS). Parameter estimate(s). Positively selected sites. (BEB) (pp > 0.8). M0 (one-ratio) (1). M3 vs. M0.
Memorial Sloan-Kettering Cancer Center. Registered Nurse Radiation Safety Questionnaire. Cognitive Test: Select the one correct response to each question.
The algorithm was implemented in the Python [30] and FORTRAN .... Patil AP, Gething PW, Piel FB, Hay SI (2011) Bayesian geostatistics in health ... Fonnesbeck C, Huard D, Patil AP (2008 ) PyMC 2.0 User's Guide: installation and tutorial.
timestampOn(verbose). Command used to define the Affymetrix chip type: chiptype
Apr 20, 2011 - alization software package, currently available for Windows, OS X, Linux, and. 1 ... The virtual appliance hosting TESeeker will then boot.1 As ...
Transcription Factor Name (Matrix ID) ... Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) ... Phospholipid transfer protein.
Additional File 4 â Prediction accuracy achieved by different features for ... trained on different feature types, namely the absolute intensity features (AI), relative ...
Additional file A8: Describing uncertainty in predicted PfPR2-10, PfEIR and PfRc ... the posterior distribution of PfPR2-10 values (panel Ai) is tightly distributed ...
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Sulfotransferase family 1A, phenol-preferring, member 1. CDNA sequence BC038479. 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1. Neuregulin 4.
PDIA3 protein disulfide isomerase family A, member 3. Cytoplasm peptidase. P18669. PGAM1 phosphoglycerate mutase 1 (brain). Cytoplasm phosphatase.
Editorial Note: Parts of this peer review file have been redacted as indicated to maintain the confidentiality of unpublished data. Reviewers' comments: Reviewer ...
patient population ... 1 subscale (brain cancer related concerns including concentration, memory, seizures, ... JP: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist.
Julie A. Schmidt et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation of Cancer and Nutrition. BMC Medicine
ADDITIONAL FILE 2
SUPPLEMENTARY FIGURES
Figure S1. Flowchart of exclusions of A: participants and B: metabolites. 1
There were 2162 samples but 8 samples contributed to the data set twice because three controls became cases and five controls were controls for two cases each.
1
C0 C2 C3 C14:1 C16 C18:1 C18:2 Alanine Arginine Asparagine Citrulline Glutamate Glutamine Glycine Histidine Isoleucine Leucine Lysine Methionine Ornithine Phenylalanine Proline Serine t4−OH−Pro Threonine Tryptophan Tyrosine Valine Creatinine Kynurenine Sarcosine Taurine ADMA SDMA lysoPC a C16:0 lysoPC a C16:1 lysoPC a C17:0 lysoPC a C18:0 lysoPC a C18:1 lysoPC a C18:2 lysoPC a C20:3 lysoPC a C20:4 PC aa C28:1 PC aa C30:0 PC aa C32:0 PC aa C32:1 PC aa C32:2 PC aa C32:3 PC aa C34:1 PC aa C34:2 PC aa C34:3 PC aa C34:4 PC aa C36:0 PC aa C36:1 PC aa C36:2 PC aa C36:3 PC aa C36:4 PC aa C36:5 PC aa C36:6 PC aa C38:0 PC aa C38:3 PC aa C38:4 PC aa C38:5 PC aa C38:6 PC aa C40:2 PC aa C40:3 PC aa C40:4 PC aa C40:5 PC aa C40:6 PC aa C42:0 PC aa C42:1 PC aa C42:2 PC aa C42:4 PC aa C42:5 PC aa C42:6 PC ae C30:0 PC ae C30:2 PC ae C32:1 PC ae C32:2 PC ae C34:0 PC ae C34:1 PC ae C34:2 PC ae C34:3 PC ae C36:0 PC ae C36:1 PC ae C36:2 PC ae C36:3 PC ae C36:4 PC ae C36:5 PC ae C38:0 PC ae C38:2 PC ae C38:3 PC ae C38:4 PC ae C38:5 PC ae C38:6 PC ae C40:1 PC ae C40:2 PC ae C40:3 PC ae C40:4 PC ae C40:5 PC ae C40:6 PC ae C42:1 PC ae C42:2 PC ae C42:3 PC ae C42:4 PC ae C42:5 PC ae C44:4 PC ae C44:5 PC ae C44:6 Hexose SM (OH) C14:1 SM (OH) C16:1 SM (OH) C22:1 SM (OH) C22:2 SM (OH) C24:1 SM C16:0 SM C16:1 SM C18:0 SM C18:1 SM C20:2 SM C24:0 SM C24:1 Total PSA
Correlation coefficient 1.0
0.5
0.0
−0.5
−1.0
Total PSA SM C24:1 SM C24:0 SM C20:2 SM C18:1 SM C18:0 SM C16:1 SM C16:0 SM (OH) C24:1 SM (OH) C22:2 SM (OH) C22:1 SM (OH) C16:1 SM (OH) C14:1 Hexose PC ae C44:6 PC ae C44:5 PC ae C44:4 PC ae C42:5 PC ae C42:4 PC ae C42:3 PC ae C42:2 PC ae C42:1 PC ae C40:6 PC ae C40:5 PC ae C40:4 PC ae C40:3 PC ae C40:2 PC ae C40:1 PC ae C38:6 PC ae C38:5 PC ae C38:4 PC ae C38:3 PC ae C38:2 PC ae C38:0 PC ae C36:5 PC ae C36:4 PC ae C36:3 PC ae C36:2 PC ae C36:1 PC ae C36:0 PC ae C34:3 PC ae C34:2 PC ae C34:1 PC ae C34:0 PC ae C32:2 PC ae C32:1 PC ae C30:2 PC ae C30:0 PC aa C42:6 PC aa C42:5 PC aa C42:4 PC aa C42:2 PC aa C42:1 PC aa C42:0 PC aa C40:6 PC aa C40:5 PC aa C40:4 PC aa C40:3 PC aa C40:2 PC aa C38:6 PC aa C38:5 PC aa C38:4 PC aa C38:3 PC aa C38:0 PC aa C36:6 PC aa C36:5 PC aa C36:4 PC aa C36:3 PC aa C36:2 PC aa C36:1 PC aa C36:0 PC aa C34:4 PC aa C34:3 PC aa C34:2 PC aa C34:1 PC aa C32:3 PC aa C32:2 PC aa C32:1 PC aa C32:0 PC aa C30:0 PC aa C28:1 lysoPC a C20:4 lysoPC a C20:3 lysoPC a C18:2 lysoPC a C18:1 lysoPC a C18:0 lysoPC a C17:0 lysoPC a C16:1 lysoPC a C16:0 SDMA ADMA Taurine Sarcosine Kynurenine Creatinine Valine Tyrosine Tryptophan Threonine t4−OH−Pro Serine Proline Phenylalanine Ornithine Methionine Lysine Leucine Isoleucine Histidine Glycine Glutamine Glutamate Citrulline Asparagine Arginine Alanine C18:2 C18:1 C16 C14:1 C3 C2 C0
Plasma metabolites and total PSA
Julie A. Schmidt et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation of Cancer and Nutrition. BMC Medicine
Plasma metabolites and total PSA
Figure S2. Partial correlation coefficients between metabolite and total PSA concentrations at baseline. Correlations between total PSA and metabolites were based on 764 controls for which total PSA was available, while correlations between metabolites included 1077 controls. The analyses were based on log-transformed data and were adjusted for age at blood collection (
